Explore the Agenda

7:00 am Doors Open for Registration, & Pre-Event Networking

7:40 am Organizer Opening Remarks

Track A: Drugging the Undruggable

How are Collaborations Advancing Clinical Translation of Induced Proximity

7:45 am Pharma Icebreaker Panel Discussion:

Senior Director External Innovation, Johnson & Johnson
Chief Business Officer, Foghorn Therapeutics
Director Search & Evaluation, Daiichi Sankyo
Executive Director Search and Evaluation - Oncology, Novartis
  • What new capabilities are pharma looking for from a partnership? Are platform deals of interest?
  • Glues, bifunctionals, antibody-degrader conjugates: what are the considerations when discussing these technologies? What evidence would make a DAC asset “partnerable”?
  • Are there unique challenges when discussing degradation within large pharma that you don’t see when modalities have more clinical validation?

8:15 am Short Comfort Break to Arrange Organized Networking Session

8:30 am Pharma Icebreaker Tables: Unlocking Unmatched Meetings

Senior Director External Innovation, Johnson & Johnson
Director Search & Evaluation, Daiichi Sankyo
Executive Director Search and Evaluation - Oncology, Novartis
  • The pharma icebreaker tables running in each track create introductions between biotech and pharma
  • Two weeks out from the conference, pharma will review attending biotech and biotech will review attending pharma, with both making selection to meet with companies they haven’t scheduled meetings with yet through the One-to-One Partnering Portal
  • With these selections, we will build a schedule of company rotations through each pharma’s table
  • Join three tables, led by three pharma, for 30 minutes each. Mixed groups rather than 1-2-1s, hear how your peers pitch themselves whilst also getting facetime with pharma yourself, first thing on day one

10:30 am Morning Break & Networking Opportunity

10:30 am One-to-One Partnering Meetings Scheduled

Meeting acceptance rate is a key KPI for a conference’s productivity. To ensure this is as high as possible the one-to-one partnering system will open 3 weeks’ from the event start.

Search the full attendee list, personalise your outreach and fill your one-to-one schedule ahead of the meeting so you can prepare.

Where do DACs fit in 2026/27 Portfolios? From Preclinical Promise to First-in-Human

11:40 am Increasing the Therapeutic Index of a Small Molecule as Precision ADCs: What Have we Learnt so Far?

Senior Vice President, Business Development, Orum Therapeutics
Chief Scientific Officer, Cullgen
Chief Scientific Officer, Nurix Therapeutics
President & Chief Executive Officer, Fortitude Biomedicines
  • Designing DACs to be a more targeted to oncogenic drivers versus traditional small molecule inhibitors
  • Discussing initial proof-of-concept case studies for DACs
  • Collaboration potential between antibody engineering and protein degradation companies
Track B: ADCs, TCEs & BsAbs in Oncology
Track C: TCEs, BsAbs & in vivo CAR-T in Autoimmunity

12:20 pm Lunch Break & Networking Opportunity

12:30 pm One-to-One Partnering Meetings Scheduled

Grab some lunch ahead of more meetings across the middle of day one. Sit down more casually with other delegates for ad hoc connections or join those you’ve prearranged to meet.

1:45 pm Company Presentation Session

What is this session?

At the intersection of innovative research and business conversations, this forum facilitates the pitching of biotech pipelines and platforms to attending pharma and investors.

How does this session work?

As you register, secure one of the 15-minute presentation slots available in this presentation session and

position your differentiation as part of the conference line-up. We will add your talk to this brochure and on our

website to showcase your differentiation in the best light and share your corporate summary with all attendees

as part of pre- and post-event content, to drive interest and follow-up in your session.

Who can present?

Those developing in-house pipeline or platform technology, without any additional service provider capabilities,

such as contract research or manufacturing.

1:45 pm Presentation Session One: Showcase Your Science

Science Partner, Flagship Pioneering

Present your company’s slides by securing a 15-minute presentation slot in front of the attending audience, within this track.

Presentation by Rapafusyn

1:45 pm Presentation Session One: Showcase Your Science

Head of Large Molecule & ADC Innovation, Eli Lilly & Co.

Present your company’s slides by securing a 15-minute presentation slot in front of the attending audience, within this track.

Presentation by SKYMAB Biotherapeutics

1:45 pm Presentation Session One: Showcase Your Science

Executive Director - Venture Fund, Boehringer Ingelheim

Present your company’s slides by securing a 15-minute presentation slot in front of the attending audience, within this track.

3:00 pm Afternoon Break & Networking Opportunity

3:00 pm One-to-One Partnering Meetings Scheduled

4:40 pm 2025/26 Deal-Making Highlights: How Did They Happen?

Chief Executive Officer, JEO Biotech Advisors
Senior Vice President, C4 Therapeutics
Head of BD&L USA & Global TA Inflammation, Boehringer Ingelheim
Head of Large Molecule & ADC Innovation, Eli Lilly & Co.
Former - Chief Executive Officer, CrossBridge Bio
President, Chief Operating & Business Officer, Epimab Biotherapeutics
  • Representing examples of successful deal-making and successful management of alliances to foster future deals, what are the learnings?
  • Sharing how early-stage programs can successfully navigate the “show me data” barrier with pharma, and the activation barrier to licencing technologies between equal sized biotech
  • Debating recent regulatory and emerging technology shifts, and how these will shape licensing deals for the discussed modalities

5:20 pm Drinks Reception

Connect more casually at the end of day one drinks reception. Enjoy an informal networking with all attending colleagues, to follow up with contacts from other partnering initiatives, catch those you haven’t already run into, and meet with old connections again in-person. Deliberately timed ahead of key events in the business development calendar, use this as an opportunity to become front-of-mind, and start conversations going into the Fall calendar.